18-365 - Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

Status: open

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome

Treatment for Acute Coronary Syndrome

Contact Us Or call 251-471-7027

Description

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.

Sponsors

This trial is sponsored by Luitpold Pharmaceuticals.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.